Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.
The efficacy and toxicity of treatment with 1400 +/- 100 MBq of Re-186-HEDP were evaluated in women with osseous metastatic breast cancer. The follow-up period was fourteen weeks. The efficacy of treatment was assessed by a) a pain and performance questionnaire that patients were asked to complete daily and b) a CT scan comparison of a randomly preselected osseous lesion before and 30 weeks after Re-186-HEDP i.v. application. The response to treatment was also evaluated by using the Kamofsky Index. Two out of fourteen women (14%) experienced loss of pain, 6 experienced obvious and 2 some improvement. No change was observed in 4 patients. Five patients manifested a flare response to treatment, with increase in pain within the first, 4 to 5 days after Re-186-HEDP administration. Five patients showed a decrease in platelet levels and absolute number of polymorphonuclear blood transfusion; no neurologic side effects were observed. Re-186-HEDP appears to be a useful new radiopharmaceutical for pain palliation induced by osseous metastases due to breast cancer. Compared to Sr-89 chloride efficacy, it provides longer-lasting analgesia, and when needed it can be reinjected with less risk due to its improved physico- and radiochemical properties.
Limouris
G S
GS
Radiology Department, Areteion Hospital, Athens University Medical Faculty, Greece.
Shukla
S K
SK
Condi-Paphiti
A
A
Gennatas
C
C
Kouvaris
I
I
Vitoratos
N
N
Manetou
A
A
Dardoufas
C
C
Rigas
V
V
Vlahos
L
L
D000328:Adult; D000698:Analgesia / Q000379:methods; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000532:radiotherapy*; D012968:Etidronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009942:Organometallic Compounds; D010014:Osteolysis; D010148:Intractable Pain; D010166:Palliative Care; D011868:Radioisotopes; D012211:Rhenium / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D013324:Strontium / Q000009:adverse effects / Q000627:therapeutic use; D013669:Technetium Tc 99m Medronate; D014055:Tomography, Emission-Computed
D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; C025700:strontium chloride; D012968:Etidronic Acid; D013669:Technetium Tc 99m Medronate; D013324:Strontium